Last reviewed · How we verify
Aggressive iron dextran supplementation
Aggressive iron dextran supplementation is a Iron replacement agent Small molecule drug developed by Shanghai East Hospital. It is currently FDA-approved for Iron deficiency anemia, Iron deficiency anemia in patients unable to tolerate or absorb oral iron.
Iron dextran is a colloidal iron-carbohydrate complex that replenishes depleted iron stores by providing bioavailable iron for hemoglobin synthesis.
Iron dextran is a colloidal iron-carbohydrate complex that replenishes depleted iron stores by providing bioavailable iron for hemoglobin synthesis. Used for Iron deficiency anemia, Iron deficiency anemia in patients unable to tolerate or absorb oral iron.
At a glance
| Generic name | Aggressive iron dextran supplementation |
|---|---|
| Sponsor | Shanghai East Hospital |
| Drug class | Iron replacement agent |
| Target | Iron (Fe3+) for hemoglobin and myoglobin synthesis |
| Modality | Small molecule |
| Therapeutic area | Hematology |
| Phase | FDA-approved |
Mechanism of action
Iron dextran is a parenteral iron replacement therapy consisting of ferric iron complexed with dextran, allowing intravenous or intramuscular administration. The iron is released from the dextran complex and incorporated into hemoglobin and other iron-dependent proteins, correcting iron deficiency anemia. 'Aggressive supplementation' refers to higher-dose or more frequent dosing regimens to rapidly restore iron stores.
Approved indications
- Iron deficiency anemia
- Iron deficiency anemia in patients unable to tolerate or absorb oral iron
Common side effects
- Injection site reactions (pain, inflammation)
- Headache
- Dizziness
- Nausea
- Hypersensitivity reactions
- Arthralgia
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Aggressive iron dextran supplementation CI brief — competitive landscape report
- Aggressive iron dextran supplementation updates RSS · CI watch RSS
- Shanghai East Hospital portfolio CI
Frequently asked questions about Aggressive iron dextran supplementation
What is Aggressive iron dextran supplementation?
How does Aggressive iron dextran supplementation work?
What is Aggressive iron dextran supplementation used for?
Who makes Aggressive iron dextran supplementation?
What drug class is Aggressive iron dextran supplementation in?
What development phase is Aggressive iron dextran supplementation in?
What are the side effects of Aggressive iron dextran supplementation?
What does Aggressive iron dextran supplementation target?
Related
- Drug class: All Iron replacement agent drugs
- Target: All drugs targeting Iron (Fe3+) for hemoglobin and myoglobin synthesis
- Manufacturer: Shanghai East Hospital — full pipeline
- Therapeutic area: All drugs in Hematology
- Indication: Drugs for Iron deficiency anemia
- Indication: Drugs for Iron deficiency anemia in patients unable to tolerate or absorb oral iron
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing